Miach Orthopaedics, Inc. is a privately held company located in Westborough, Massachusetts, dedicated to developing bio-engineered surgical implants for connective tissue restoration. The company’s initial focus is the Bridge-Enhanced® ACL Restoration (BEAR®) Implant, which represents a paradigm shift in the treatment of ACL tears from reconstruction to restoration. The BEAR technology was pioneered by Martha Murray, MD, founder of Miach Orthopaedics, at the Boston Children’s Hospital Department of Orthopaedic Surgery, with initial research funding provided by the NFL Players Association, Boston Children’s Hospital and the National Institutes of Health.
Martha Shadan joined Miach Orthopaedics as president and chief executive officer in January 2019. During 2018, Shadan served as global vice president of marketing at Smith & Nephew plc, a role she assumed after the company acquired Rotation Medical, where she was president and CEO. Shadan led Rotation Medical through FDA approval and commercialization of the Rotation Medical Bioinductive Implant for rotator cuff tears (now known as REGENETEN™), as well as the company’s acquisition by Smith & Nephew in December 2017.
Shadan has more than three decades of experience in the life science industry as a business leader in a variety of both large and start-up organizations. Prior to joining Rotation Medical, she was the president of the Trauma Division at Zimmer where she managed the P&L for the global business. Shadan served at Covidien as vice president/general manager of Vascular Therapies and vice president/general manager of BioSurgery and Sports Surgery. Other companies that have benefited from Shadan’s experience and leadership include Bristol Myers Squibb Co. and Merck Millipore.
Shadan is the chairwoman of the Board of Directors for a medical device start-up, IlluminOss. She is actively involved with the Advanced Medical Technology Association (AdvaMed), serving on the Board of Directors since 2017; being a member of the Accel Board of Directors since 2015 and currently serving as its chairwoman. Accel is the division within AdvaMed dedicated to addressing the unique needs and challenges of smaller medical technology manufacturers. Shadan chairs the Diversity and Inclusion Committee for AdvaMed and is a founding member of the Leadership Circle for the Women’s Executive Network (WEN). She is also a board advisor for several other companies.
Shadan holds a master of business administration from Northeastern University, master of science in biology from Michigan State University, and bachelor of science in biology from the University of New Hampshire.
Christopher Joyce joined Miach Orthopaedics as vice president and chief financial officer in August 2021. He brings more than 30 years of experience in managing all aspects of finance and operations from a firm's inception through commercialization via his work with three venture backed startups and public NYSE company.
He has raised over $2 billion of public and private debt and equity, including two public offerings and over $200 million of venture financing. Joyce has a proven track record as a partner to the CEO, raising capital; building teams; negotiating deals; managing accounting, tax, human resources and legal; and building an operational infrastructure. For the past two years, he has served as a consulting CFO for several biotech and medical device startups. Prior to that, he was on the founding teams as CFO of FRX Polymers, a material science company, and two medical device companies, Elemé Medical and Percardia. Joyce started his career with XTRA Corporation, a NYSE company, serving his last seven years as vice president and treasurer.
He earned his master of business administration degree from Babson College and his bachelor of business degree from the University of Massachusetts.
Michael McNulty joined Miach Orthopaedics as vice president of sales and marketing in October 2019. He is a commercial leader who is skilled at hiring, developing and motivating his team to consistently deliver exceptional sales performance, and he is experienced at bringing a totally new orthopaedic treatment to market.
McNulty brings more than 20 years of global medical device commercial experience at both large and small companies. Most recently, McNulty served as senior director of sales in the Biologics Division at Smith & Nephew following the company’s acquisition of Rotation Medical, where he served as vice president of sales and marketing. Under his commercial leadership, sales of the Rotation Medical Bioinductive Implant for rotator cuff tears (now known as REGENETEN) outperformed expectations at both Rotation Medical and Smith & Nephew. Previously, McNulty served as vice president of sales for Arstasis, where he was responsible for market development, commercial launch, sales training and sales management. He has also held multiple roles at Cordis, a Johnson & Johnson Company, where he helped launch several disruptive technologies to the market and led sales training and sales management for both the Cardiology and Endovascular divisions.
McNulty served as an officer in the Armor Cavalry Branch of the United States Army from 1995-1998. He holds a Bachelor of Arts degree and graduated with honors from Clemson University.
Michael O’Hara joined Miach Orthopaedics as vice president of quality assurance in February 2019. For nearly seven years, he served as senior director of quality assurance for TransMedics, Inc., where he led premarket approval (PMA) submissions for two products and oversaw U.S. Food and Drug Administration manufacturing inspections.
O’Hara has more than 23 years of experience in compliance, product quality, quality systems and customer satisfaction. Prior to joining TransMedics, he served as director of global quality assurance for ABIOMED, where he was responsible for the strategic planning and organizational development of the global quality team and led successful, unannounced FDA and PMDA inspections. He has also served in quality leadership roles at Medtronic and Baxter.
O’Hara is a certified quality engineer, a certified lead auditor, and a certified Lean (Six) Sigma Green Belt. He holds a master of science in bioengineering from the University of Illinois at Chicago and a bachelor of science in biomedical engineering from Marquette University in Milwaukee.
Rita Paparazzo, MBA, joined Miach Orthopaedics as senior director of clinical operations in March 2019. She has a demonstrated history of working in the biotechnology industry and a strong background in orthopedics, serving in various clinical and research roles at Boston Biomedical Associates since 2009. There, she successfully led all aspects of clinical operations and executed clinical trials, including an investigational device exemption trial from its inception through to the product’s PMA.
Prior to joining Boston Biomedical, she served in senior research and operations roles at Inverness Medical/Biosite Inc., where she managed clinical studies from start to finish. Earlier in her career, she supported research and operations at Pfizer and Avecia Biotechnology.
Paparazzo holds a master of business administration from Regis University and bachelor of science in biotechnology from Worcester State College.
Stephen Wohlert, PhD, joined Miach Orthopaedics as vice president of manufacturing in January 2020. He is an experienced leader with a successful track record of transferring concepts to product development and commercialization, and he possesses unique expertise in collagen manufacturing processes.
Dr. Wohlert brings more than 15 years of experience in medical device and over-the-counter drug concept and product development. Most recently he served as director of research and development at Professional Disposable International (PDI) in Montvale, New Jersey. Additional experience includes director of research and development positions at Medtronic/Covidien in Trévoux, France, and North Haven, Connecticut, and project leader at Ethicon Norderstedt in Germany.
He holds a doctorate degree in chemistry from the Technical University of Aachen in Germany and a master’s degree in chemistry from Christian Albrecht University of Kiel in Germany.
Martha Shadan joined Miach Orthopaedics as president and chief executive officer in January 2019. During 2018, Shadan served as global vice president of marketing at Smith & Nephew plc, a role she assumed after the company acquired Rotation Medical, where she was president and CEO. Shadan led Rotation Medical through FDA approval and commercialization of the Rotation Medical Bioinductive Implant for rotator cuff tears (now known as REGENETEN), as well as the company’s acquisition by Smith & Nephew in December 2017.
Martha Murray, MD, is founder of Miach Orthopaedics. She is a professor of orthopaedic surgery at Boston Children’s Hospital/Harvard Medical School. Dr. Murray has specialized in the care of patients with knee injuries, and she is internationally recognized as an expert in the care of sports injuries of the knee, including ACL, meniscus and osteochondritis dissecans lesions. Dr. Murray pioneered the BEAR Implant with initial research funding provided by the NFL Players Association, Boston Children’s Hospital and the National Institutes of Health.
Pieter Wolters has served as managing director at DSM Venturing since 2012 and also serves on the boards of directors of Interface Biologics, Bio2 Technologies, Frontier Nutrition, Leading Edge Crystal Technologies, and until the recent acquisition by Teleflex, Essential Medical. Before DSM, he was a repeat life science startup entrepreneur, including co-founder and CEO of OrthAlign and IsoTis OrthoBiologics. He earned his master’s degree in law from Leiden University, The Netherlands.
Joyce Erony has more than 30 years of experience as a principal in investing activities, business development and investment banking. Prior to founding Majalin in 2015, she was a managing director at Signet Healthcare Partners, a growth capital healthcare fund in New York. Erony has led or co-led investments in Inspire Medical Systems (IPO), Essential Medical (sale), Icon Biosystems (sale), Peak Surgical (sale), Dow Pharma Sciences (sale), Anteis (sale) and Atlantis (sale). She is currently a director of Inspire Medical Systems and Miach. Based in New York City, Erony leads the firm’s activities in med tech and specialty pharma. Previously, Erony was a strategic advisor to Alcon Labs and a managing director at Citigroup, responsible for the Bank’s activities in specialty pharmaceuticals and medical devices.
Sean Sansiveri directs the NFLPA’s health, safety and medical research initiatives, including implementation of standardized protocols governing the evaluation and management of concussions and a long-term research partnership with Harvard University and Harvard Medical School. He is also an adjunct professor for Georgetown University, School of Continuing Studies.
Dr. Richard Parker has dedicated his practice to the field of sports medicine, sports-related injuries and arthroscopic knee surgery. He served as head team physician for the NBA’s Cleveland Cavaliers from 2000-2017, is a national and international presenter and has written more than 200 publications. He earned his medical degree from The Ohio State University.
Kristine Ilaria is a seasoned healthcare executive with experience leading strategy, finance and acquisitions. She currently works at Smith & Nephew as vice president of corporate development. Previously, she worked at Stryker in a variety of roles across its orthopaedics businesses.
Dr. Amendola is a professor of orthopaedic surgery, chief of the Division of Sports Medicine and director of the Urbaniak Sports Sciences Institute at Duke University. His clinical and research interests focus on improving the understanding, prevention, treatment, and rehabilitation of sports and activity-related problems of the knee and ankle.
Dr. Axe is a Hughston Clinic fellowship trained sports orthopedist with 35 years of attending experience. He is a founding partner of First State Orthopaedics and a University of Delaware Professor of Physical Therapy with more than 85 publications while maintaining a private practice. The AOSSM has recognized Dr. Axe with both the Mr. Sports Medicine and Brady Awards.
Dr. Hannafin is an attending orthopaedic surgeon and senior scientist at the Hospital for Special Surgery. She serves as the Orthopedic Director of the Women’s Sports Medicine Center and the Medical Director of the HSS Outpatient Center in Stamford, CT. She is a Professor of Orthopedic Surgery at Weill Cornell Medical College. Her interests include injury treatment and prevention in athletes and active individuals. She has served as a team physician for the U.S. Olympic team and currently serves as Head Team Physician for U.S. Rowing and the WNBA New York Liberty.
Dr. Wasserstein is an orthopaedic surgeon and sports medicine specialist at the University of Toronto. His clinical practice includes lower extremity soft-tissue trauma and reconstruction, with a focus on knee and foot/ankle. His research interests include understanding the natural history of soft-tissue injuries and identifying which patients benefit most from early surgical intervention.
Dr. Wojtys a professor in the University of Michigan’s Department of Orthopaedic Surgery. His research interests include female knee injuries and anterior cruciate ligament injuries. He currently serves on the NFL Health and Safety Committee and the medical publishing board of trustees for American Orthopaedic Society for Sports Medicine (AOSSM).